Characterization of Brain Metastases

This study is enrolling participants by invitation only.

Sponsors and Collaborators:	Norwegian University of Science and Technology The Royal Norwegian Ministry of Health
Information provided by:	Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:	NCT00184275

Purpose

The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.

Condition
Neoplasm Metastasis Lung Neoplasms Breast Neoplasms Melanoma

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer Lung Cancer Melanoma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Brain Metastases Tissue Characterized by High-Resolution Magic Angle Spinning MR and Micro Array

Further study details as provided by Norwegian University of Science and Technology:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

frozen tumor tissue samples

Estimated Enrollment:	60
Study Start Date:	May 2005
Estimated Study Completion Date:	December 2010
Primary Completion Date:	May 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients with brain metastases

Criteria

Inclusion Criteria:

Clinical diagnosis of brain metastases

Exclusion Criteria:

children
pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184275

Locations

Norway
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, Norway, N-7489

Sponsors and Collaborators

Norwegian University of Science and Technology

The Royal Norwegian Ministry of Health

Investigators

Study Director:	Steinar Lundgren, MD PhD	Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Study Chair:	Ingrid S Gribbestad, PhD	Norwegian University of Science and Technology, Faculty of Medicine

More Information

Responsible Party:	Norwegian University of Science and Technology, Faculty of Medicine ( Torill Sjobakk )
Study ID Numbers:	12621
Study First Received:	September 13, 2005
Last Updated:	January 23, 2008
ClinicalTrials.gov Identifier:	NCT00184275
Health Authority:	Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:

Brain metastasis
HR MAS spectroscopy
Tissue micro array
DNA micro array

Study placed in the following topic categories:

Thoracic Neoplasms
Skin Diseases
Breast Neoplasms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Respiratory Tract Diseases
Lung Neoplasms

Nevus, Pigmented
Lung Diseases
Neoplasms, Germ Cell and Embryonal
Neoplasm Metastasis
Neuroepithelioma
Nevus
Breast Diseases

Additional relevant MeSH terms:

Respiratory Tract Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes

Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on January 14, 2009